Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells

Frontiers in Immunology

Volumn 9, Issue , 2018, Pages

  Snyder, Kristin M ^a   Hullsiek, Robert ^a   Mishra, Hemant K ^a   Mendez, Daniel C ^a   Li, Yunfang ^a   Rogich, Allison ^a   Kaufman, Dan S ^b   Wu, Jianming ^a   Walcheck, Bruce ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

ADCC; antibody; FcR; immunotherapy; NK cell

Indexed keywords

FC RECEPTOR; FCGR1A PROTEIN, HUMAN; FCGR3A PROTEIN, HUMAN; FUSION PROTEIN; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CELL CULTURE TECHNIQUE; CELL LINE; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INDUCED PLURIPOTENT STEM CELL; METABOLISM; NATURAL KILLER CELL; NEOPLASM; PROCEDURES; PROTEIN ENGINEERING;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL CULTURE TECHNIQUES; CELL LINE; HUMANS; IMMUNOTHERAPY; INDUCED PLURIPOTENT STEM CELLS; KILLER CELLS, NATURAL; NEOPLASMS; PROTEIN ENGINEERING; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS;

EID: 85058883471     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2018.02873     Document Type: Article

References (50)

1. Carotta S. Targeting NK cells for anticancer immunotherapy: clinical and preclinical approaches. Front Immunol. (2016) 7:152. 10.3389/fimmu.2016.0015227148271
2. Alderson KL Sondel PM. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol. (2011) 2011:379123. 10.1155/2011/37912321660134
3. Long EO Kim HS Liu D Peterson ME Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol. (2013) 31:227–58. 10.1146/annurev-immunol-020711-07500523516982
4. Wang W Erbe AK Hank JA Morris ZS Sondel PM. NK Cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol. (2015) 6:368. 10.3389/fimmu.2015.0036826284063
5. Lanier LL Yu G Phillips JH. Co-association of CD3 zeta with a receptor (CD16) for IgG Fc on human natural killer cells. Nature (1989) 342:803–5. 10.1038/342803a02532305
6. Anderson P Caligiuri M O'Brien C Manley T Ritz J Schlossman SF. Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells. Proc Natl Acad Sci USA. (1990) 87:2274–8. 2138330
7. Letourneur O Kennedy IC Brini AT Ortaldo JR O'Shea JJ Kinet JP. Characterization of the family of dimers associated with Fc receptors (Fc epsilon RI and Fc gamma RIII). J Immunol. (1991) 147:2652–6. 1833456
8. Hou X Dietrich J Geisler NO. The cytoplasmic tail of FcgammaRIIIAalpha is involved in signaling by the low affinity receptor for immunoglobulin G. J Biol Chem. (1996) 271:22815–22. 8798459
9. Li X Baskin JG Mangan EK Su K Gibson AW Ji C et al. The unique cytoplasmic domain of human FcgammaRIIIA regulates receptor-mediated function. J Immunol. (2012) 189:4284–94. 10.4049/jimmunol.120070423024279
10. Wang Y Wu J Newton R Bahaie NS Long C Walcheck B. ADAM17 cleaves CD16b (FcgammaRIIIb) in human neutrophils. Biochim Biophys Acta (2013) 1833:680–5. 10.1016/j.bbamcr.2012.11.02723228566
11. Romee R Foley B Lenvik T Wang Y Zhang B Ankarlo D et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood (2013) 121:3599–608. 10.1182/blood-2012-04-42539723487023
12. Peruzzi G Femnou L Gil-Krzewska A Borrego F Weck J Krzewski K et al. Membrane-type 6 matrix metalloproteinase regulates the activation-induced downmodulation of CD16 in human primary NK cells. J Immunol. (2013) 191:1883–94. 10.4049/jimmunol.130031323851692
13. Lajoie L Congy-Jolivet N Bolzec A Gouilleux-Gruart V Sicard E Sung HC et al. ADAM17-mediated shedding of FcgammaRIIIA on human NK cells: identification of the cleavage site and relationship with activation. J Immunol. (2014) 192:741–51. 10.4049/jimmunol.130102424337742
14. Jing Y Ni Z Wu J Higgins L Markowski TW Kaufman DS et al. Identification of an ADAM17 cleavage region in human CD16 (FcgammaRIII) and the engineering of a non-cleavable version of the receptor in NK cells. PLoS ONE (2015) 10:e0121788. 10.1371/journal.pone.012178825816339
15. Lai P Rabinowich H Crowley-Nowick PA Bell MC Mantovani G Whiteside TL. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res. (1996) 2:161–73. 9816103
16. Veeramani S Wang SY Dahle C Blackwell S Jacobus L Knutson T et al. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood (2011) 118:3347–9. 10.1182/blood-2011-05-35141121768303
17. Cox MC Battella S La Scaleia R Pelliccia S Di Napoli A Porzia A et al. Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients. Oncoimmunology (2015) 4:e990773. 10.4161/2162402X.2014.99077325949906
18. Granzin M Soltenborn S Muller S Kollet J Berg M Cerwenka A et al. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy. Cytotherapy (2015) 17:621–32. 10.1016/j.jcyt.2015.03.61125881519
19. Felices M Chu S Kodal B Bendzick L Ryan C Lenvik AJ et al. IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer. Gynecol Oncol. (2017) 145:453–61. 10.1016/j.ygyno.2017.02.02828236454
20. Mishra HK Pore N Michelotti EF Walcheck B. Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNgamma production by human NK cells in the presence of antibody-bound tumor cells. Cancer Immunol Immunother. (2018) 67:1407–16. 10.1007/s00262-018-2193-129978334
21. Wu J Edberg JC Redecha PB Bansal V Guyre PM Coleman K et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. (1997) 100:1059–70. 10.1172/JCI1196169276722
22. Koene HR Kleijer M Algra J Roos D von dem Borne AE de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood (1997) 90:1109–14. 9242542
23. Dong C Ptacek TS Redden DT Zhang K Brown EE Edberg JC et al. Fcgamma receptor IIIa single-nucleotide polymorphisms and haplotypes affect human IgG binding and are associated with lupus nephritis in African Americans. Arthr Rheumatol. (2014) 66:1291–9. 10.1002/art.3833724782186
24. Nimmerjahn F Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. (2008) 8:34–47. 10.1038/nri220618064051
25. Bruhns P Iannascoli B England P Mancardi DA Fernandez N Jorieux S et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood (2009) 113:3716–25. 10.1182/blood-2008-09-17975419018092
26. Kiyoshi M Caaveiro JM Kawai T Tashiro S Ide T Asaoka Y et al. Structural basis for binding of human IgG1 to its high-affinity human receptor FcgammaRI. Nat Commun. (2015) 6:6866. 10.1038/ncomms786625925696
27. Binyamin L Alpaugh RK Hughes TL Lutz CT Campbell KS Weiner LM. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol. (2008) 180:6392–401. 10.4049/jimmunol.180.9.639218424763
28. Ni Z Knorr DA Kaufman DS. Hematopoietic and nature killer cell development from human pluripotent stem cells. Methods Mol Biol. (2013) 1029:33–41. 10.1007/978-1-62703-478-4_323756940
29. Knorr DA Ni Z Hermanson D Hexum MK Bendzick L Cooper LJ et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Transl Med. (2013) 2:274–83. 10.5966/sctm.2012-008423515118
30. Ni Z Knorr DA Bendzick L Allred J Kaufman DS. Expression of chimeric receptor CD4zeta by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. Stem cells (2014) 32:1021–31. 10.1002/stem.1611
31. Hermanson DL Bendzick L Pribyl L McCullar V Vogel RI Miller JS et al. Induced pluripotent stem cell-derived natural killer cells for treatment of ovarian cancer. Stem Cells (2016) 34:93–101. 10.1002/stem.223026503833
32. Woll PS Grzywacz B Tian X Marcus RK Knorr DA Verneris MR et al. Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood (2009) 113:6094–101. 10.1182/blood-2008-06-16522519365083
33. Harrison PT Allen JM. High affinity IgG binding by FcgammaRI (CD64) is modulated by two distinct IgSF domains and the transmembrane domain of the receptor. Protein Eng. (1998) 11:225–32. 9613847
34. Wang R Jaw JJ Stutzman NC Zou Z Sun PD. Natural killer cell-produced IFN-gamma and TNF-alpha induce target cell cytolysis through up-regulation of ICAM-1. J Leukoc Biol. (2012) 91:299–309. 10.1189/jlb.061130822045868
35. Carlsten M Childs RW. Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications. Front Immunol. (2015) 6:266. 10.3389/fimmu.2015.0026626113846
36. Zeng J Tang SY Toh LL Wang S. Generation of “Off-the-Shelf” natural killer cells from peripheral blood cell-derived induced pluripotent stem cells. Stem Cell Rep. (2017) 9:1796–812. 10.1016/j.stemcr.2017.10.02029173894
37. Hermanson DL Kaufman DS. Utilizing chimeric antigen receptors to direct natural killer cell activity. Front Immunol. (2015) 6:195. 10.3389/fimmu.2015.0019525972867
38. Li Y Hermanson DL Moriarity BS Kaufman DS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell (2018) 23:181–192.e5. 10.1016/j.stem.2018.06.00230082067
39. Strauss-Albee DM Horowitz A Parham P Blish CA. Coordinated regulation of NK receptor expression in the maturing human immune system. J Immunol. (2014) 193:4871–9. 10.4049/jimmunol.140182125288567
40. Horowitz A Strauss-Albee DM Leipold M Kubo J Nemat-Gorgani N Dogan OC et al. Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci Transl Med. (2013) 5:208ra145. 10.1126/scitranslmed.300670224154599
41. Strauss-Albee DM Fukuyama J Liang EC Yao Y Jarrell JA Drake AL et al. Human NK cell repertoire diversity reflects immune experience and correlates with viral susceptibility. Sci Transl Med. (2015) 7:297ra115. 10.1126/scitranslmed.aac572226203083
42. Klingemann H Boissel L Toneguzzo F. Natural killer cells for immunotherapy - advantages of the NK-92 cell line over blood NK Cells. Front Immunol. (2016) 7:91. 10.3389/fimmu.2016.0009127014270
43. Zhang C Oberoi P Oelsner S Waldmann A Lindner A Tonn T et al. Chimeric antigen receptor-engineered NK-92 Cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity. Front Immunol. (2017) 8:533. 10.3389/fimmu.2017.0053328572802
44. Seidel UJ Schlegel P Lang P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol. (2013) 4:76. 10.3389/fimmu.2013.0007623543707
45. Bhat R Watzl C. Serial killing of tumor cells by human natural killer cells–enhancement by therapeutic antibodies. PLoS ONE (2007) 2:e326. 10.1371/journal.pone.000032617389917
46. Vanherberghen B Olofsson PE Forslund E Sternberg-Simon M Khorshidi MA Pacouret S et al. Classification of human natural killer cells based on migration behavior and cytotoxic response. Blood (2013) 121:1326–34. 10.1182/blood-2012-06-43985123287857
47. Hsu HT Mace EM Carisey AF Viswanath DI Christakou AE Wiklund M et al. NK cells converge lytic granules to promote cytotoxicity and prevent bystander killing. J Cell Biol. (2016) 215:875–89. 10.1083/jcb.20160413627903610
48. Srpan K Ambrose A Karampatzakis A Saeed M Cartwright ANR Guldevall K et al. Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells. J Cell Biol. (2018) 217:3267. 10.1083/jcb.20171208529967280
49. Battella S Cox MC Santoni A Palmieri G. Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions. J Leukoc Biol. (2016) 99:87–96. 10.1189/jlb.5VMR0415-141R26136506
50. Angelos MG Kaufman DS. Pluripotent stem cell applications for regenerative medicine. Curr Opin Organ Transplant. (2015) 20:663–70. 10.1097/MOT.000000000000024426536430